Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
| (in thousands, except for share and per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 18,906 | 16,213 | 36,917 | 31,344 |
| Operating expenses: | ||||
| Sales and marketing | 12,124 | 11,489 | 23,707 | 21,894 |
| Research and development | 6,898 | 6,845 | 14,087 | 14,285 |
| General and administrative | 5,027 | 6,068 | 9,871 | 10,114 |
| Total operating expenses | 24,049 | 24,402 | 47,665 | 46,293 |
| Loss from continuing operations | (5,143) | (8,189) | (10,748) | (14,949) |
| Interest income | 523 | 718 | 1,088 | 1,511 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Neuropace, Inc.'s R&D?
- Neuropace, Inc. (NPCE) reported R&D of $6.9M in Q2 2026.
- How has Neuropace, Inc.'s R&D changed year-over-year?
- Neuropace, Inc.'s R&D increased by 0.8% year-over-year, from $6.85M to $6.9M.
- What is the long-term trend for Neuropace, Inc.'s R&D?
- Over 4 years (2021 to 2025), Neuropace, Inc.'s R&D has grown at a 11.2% compound annual growth rate (CAGR), from $18.21M to $27.89M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Neuropace, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude